INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Directory07Corporate Insiders08Government Money09Political Influence10Institutions11Washington Network12Follow the Power13Disclosure Clock14AI Investigator15Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
01Overview02Follow the Money03Daily Brief04Live05Congress06Directory07Corporate Insiders08Government Money09Political Influence10Institutions11Washington Network12Follow the Power13Disclosure Clock14AI Investigator15Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Data sources
SEC FORM 447m ago
HOUSE PTR46m ago
SEC 13F46m ago
ROBINHOOD CHAIN46m ago
SEC FORM 4/Open-market saleVerified data

Roberts Zachary sold ALLO

EVP of R&D · Allogene Therapeutics, Inc. · Common Stock

Side
SELL
Value
$41K
Shares
26.3K
Price
$1.56
Executed
Jan 21, 2026
Disclosed
Jan 23, 2026
Disclosure timeline2 days from execution to publication · legal deadline 2 business days
Jan 21 executedJan 23, 2026 disclosed

ALLO · daily

Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.

Insider Score

Experimental signal
21/ 100 · ROUTINE
Methodology →
  • Transaction type+12 / 20

    Open-market sale

  • Relative size+1 / 25

    $41K reported value · 4.1% of prior position

  • Filing timing0 / 15

    Disclosed 2 business days after execution (deadline: 2)

  • Historical behavior+8 / 15

    First recorded trade by this actor in this security

  • Frequency & clustering0 / 15

    No clustered activity in the dataset

  • Market events0 / 10

    No material company filing within 60 days after the trade

    • The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.

    Other disclosed activity · ALLO

    ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
    21
    PM
    Parker Geoffrey M.CHIEF FINANCIAL OFFICER
    ALLOAllogene Therapeutics, Inc.
    Open-market sale
    		SELL$49K
    36.3K sh
    		Oct 21, 2026Oct 23, 2026
    traded Oct 21, 2026
    		+2dSEC FORM 4

    Evidence

    25
    YA
    Yoshiyama AnnieSVP, Finance
    ALLOAllogene Therapeutics, Inc.
    Open-market sale
    		SELL$22K
    9,586 sh
    		Apr 21, 2026Apr 23, 2026
    traded Apr 21, 2026
    		+2dSEC FORM 4

    Evidence

    17
    BM
    Beneski Benjamin MachinasSVP, Chief Technical Officer
    ALLOAllogene Therapeutics, Inc.
    Open-market sale
    		SELL$7,168
    2,867 sh
    		Mar 31, 2026Apr 2, 2026
    traded Mar 31, 2026
    		+2dSEC FORM 4

    Evidence

    21
    BM
    Beneski Benjamin MachinasSVP, Chief Technical Officer
    ALLOAllogene Therapeutics, Inc.
    Open-market sale
    		SELL$19K
    7,132 sh
    		Mar 2, 2026Mar 4, 2026
    traded Mar 2, 2026
    		+2dSEC FORM 4

    Evidence

    Evidence

    Verified data

    Read directly from the primary public document; every field below is as reported by the filer.

    Source

    Document
    SEC Form 4
    Publisher
    U.S. Securities and Exchange Commission (EDGAR)
    Document ID
    0001851044-26-000003
    Machine-readable
    Structured copy

    Timestamps

    Event (reported)
    Jan 21, 2026
    Published
    Jan 23, 2026
    Ingested by INSIDER
    Nov 5, 04:21 UTC
    Last re-read
    Nov 5, 04:21 UTC

    Extracted facts

    Filer
    Roberts Zachary
    Role
    EVP of R&D
    Transaction
    Open-market saleAs filed: “S”
    Asset
    Allogene Therapeutics, Inc.
    Ticker
    ALLO
    Shares
    26.3K
    Price per share
    $1.56
    Value
    $40,980
    Execution date (reported)
    Jan 21, 2026
    Owned after transaction
    616.9K shares
    Days from execution to publication
    2

    Calculation

    Value = shares × reported price per share

    • Shares: 26.3K
    • Price: $1.56

    = $40,980

    What this establishes

    Roberts Zachary filed this Form 4 reporting a open-market sale of ALLO on Jan 21, 2026. It became public on Jan 23, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.

    Extraction

    Method
    Form 4 XML
    Confidence
    1.00
    EVP of R&D
    Roberts Zacharycik:0001851044
    Issuer
    Allogene Therapeutics, Inc.cik:0001737287

    Revision history · 0

    No field has changed since this record was first ingested.

    Company events

    No records

    No material filings recorded for this issuer.